Francois Le Loarer

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1716775/publications.pdf

Version: 2024-02-01

54 papers	2,667 citations	257101 24 h-index	197535 49 g-index
64 all docs	64 docs citations	64 times ranked	2976 citing authors

#	Article	IF	Citations
1	New developments in the pathology and molecular biology of retroperitoneal sarcomas. European Journal of Surgical Oncology, 2023, 49, 1053-1060.	0.5	6
2	Soft Tissue Sarcomas: The Role of Quantitative MRI in Treatment Response Evaluation. Academic Radiology, 2022, 29, 1065-1084.	1.3	10
3	Thyroidâ€like follicular renal cell carcinoma with sarcomatoid differentiation and an aggressive clinical course: a case report confirming the presence of the EWSR1::PATZ1 fusion gene. Histopathology, 2022, 80, 745-748.	1.6	6
4	Natural speed of growth of untreated soft-tissue sarcomas: A dimension-based imaging analysis. European Journal of Radiology, 2022, 146, 110082.	1.2	3
5	Wholistic approach: Transcriptomic analysis and beyond using archival material for molecular diagnosis. Genes Chromosomes and Cancer, 2022, 61, 382-393.	1.5	18
6	Advances in the classification of round cell sarcomas. Histopathology, 2022, 80, 33-53.	1.6	14
7	Clinicopathologic and Molecular Study of Hybrid Nerve Sheath Tumors Reveals Their Common Association With Fusions Involving VGLL3. American Journal of Surgical Pathology, 2022, 46, 591-602.	2.1	8
8	Novel <scp>EWSR1::UBP1</scp> fusion expands the spectrum of spindle cell rhabdomyosarcomas. Genes Chromosomes and Cancer, 2022, 61, 200-205.	1.5	6
9	Recurrent YAP1::MAML2 fusions in â€œnodular necrotizingâ€•variants of myxoinflammatory fibroblastic sarcoma: a comprehensive study of 7 cases. Modern Pathology, 2022, 35, 1398-1404.	2.9	13
10	Pembrolizumab in soft-tissue sarcomas with tertiary lymphoid structures: a phase 2 PEMBROSARC trial cohort. Nature Medicine, 2022, 28, 1199-1206.	15.2	88
11	No Geographical Inequalities in Survival for Sarcoma Patients in France: A Reference Networksâ€™ Outcome?. Cancers, 2022, 14, 2620.	1.7	4
12	Update on Mesenchymal Lesions of the Lower Female Genital Tract. Surgical Pathology Clinics, 2022, 15, 341-367.	0.7	2
13	Mature tertiary lymphoid structure is a specific biomarker of cancer immunotherapy and does not predict outcome to chemotherapy in non-small-cell lung cancer. Annals of Oncology, 2022, 33, 1084-1085.	0.6	10
14	Circulating L-arginine predicts the survival of cancer patients treated with immune checkpoint inhibitors. Annals of Oncology, 2022, 33, 1041-1051.	0.6	22
15	Specific and Sensitive Diagnosis of BCOR-ITD in Various Cancers by Digital PCR. Frontiers in Oncology, 2021, 11, 645512.	1.3	8
16	Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network. PLoS ONE, 2021, 16, e0246958.	1.1	131
17	Infantile Rhabdomyosarcomas With VGLL2 Rearrangement Are Not Always an Indolent Disease. American Journal of Surgical Pathology, 2021, 45, 854-867.	2.1	12
18	Determinants of the access to remote specialised services provided by national sarcoma reference centres. BMC Cancer, 2021, 21, 631.	1.1	14

#	Article	IF	Citations
19	SWI/SNF-deficient thoraco-pulmonary neoplasms. Seminars in Diagnostic Pathology, 2021, 38, 183-194.	1.0	14
20	Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expression. Nature Cancer, 2021, 2, 794-802.	5.7	173
21	Plasma proteomics identifies leukemia inhibitory factor (LIF) as a novel predictive biomarker of immune-checkpoint blockade resistance. Annals of Oncology, 2021, 32, 1381-1390.	0.6	33
22	Implementing a Machine Learning Strategy to Predict Pathologic Response in Patients With Soft Tissue Sarcomas Treated With Neoadjuvant Chemotherapy. JCO Clinical Cancer Informatics, 2021, 5, 958-972.	1.0	3
23	Superficial CD34â€positive fibroblastic tumor and PRDM10â€rearranged soft tissue tumor are overlapping entities: a comprehensive study of 20 cases. Histopathology, 2021, 79, 810-825.	1.6	26
24	The SS18-SSX Antibody Has Perfect Specificity for the SS18-SSX Fusion Protein. American Journal of Surgical Pathology, 2021, 45, 582-584.	2.1	19
25	A subset of epithelioid and spindle cell rhabdomyosarcomas is associated with TFCP2 fusions and common ALK upregulation. Modern Pathology, 2020, 33, 404-419.	2.9	80
26	The current landscape of rhabdomyosarcomas: an update. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 97-108.	1.4	97
27	ATR Inhibition Broadly Sensitizes Soft-Tissue Sarcoma Cells to Chemotherapy Independent of Alternative Lengthening Telomere (ALT) Status. Scientific Reports, 2020, 10, 7488.	1.6	16
28	Effect of decalcification protocols on immunohistochemistry and molecular analyses of bone samples. Modern Pathology, 2020, 33, 1505-1517.	2.9	44
29	Recurrent novel THBS1-ADGRF5 gene fusion in a new tumor subtype â€œAcral FibroChondroMyxoid Tumorsâ€• Modern Pathology, 2020, 33, 1360-1368.	2.9	12
30	The combination of radiotherapy and ALK inhibitors is effective in the treatment of intraosseous rhabdomyosarcoma with FUSâ€TFCP2 fusion transcript. Pediatric Blood and Cancer, 2020, 67, e28185.	0.8	24
31	NFATc2-rearranged sarcomas: clinicopathologic, molecular, and cytogenetic study of 7 cases with evidence of AGGRECAN as a novel diagnostic marker. Modern Pathology, 2020, 33, 1930-1944.	2.9	38
32	SRF-FOXO1 and SRF-NCOA1 Fusion Genes Delineate a Distinctive Subset of Well-differentiated Rhabdomyosarcoma. American Journal of Surgical Pathology, 2020, 44, 607-616.	2.1	37
33	SMARCA4-Deficient Sarcoma. Encyclopedia of Pathology, 2020, , 1-8.	0.0	0
34	Rhabdoid Tumor, Soft Tissue. Encyclopedia of Pathology, 2020, , 1-9.	0.0	0
35	High-grade soft-tissue sarcoma: optimizing injection improves MRI evaluation of tumor response. European Radiology, 2019, 29, 545-555.	2.3	13
36	Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study. European Journal of Cancer, 2019, 119, 151-157.	1.3	103

#	Article	IF	Citations
37	Abnormal vascularization of soft-tissue sarcomas on conventional MRI: Diagnostic and prognostic values. European Journal of Radiology, 2019, 117, 112-119.	1.2	6
38	Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Annals of Oncology, 2019, 30, 1143-1153.	0.6	191
39	Clinicopathologic Features of CIC-NUTM1 Sarcomas, a New Molecular Variant of the Family of CIC-Fused Sarcomas. American Journal of Surgical Pathology, 2019, 43, 268-276.	2.1	96
40	Imaging features of SMARCA4-deficient thoracic sarcomas: a multi-centric study of 21 patients. European Radiology, 2019, 29, 4730-4741.	2.3	33
41	Clinicopathologic and Molecular Features of a Series of 41 Biphenotypic Sinonasal Sarcomas Expanding Their Molecular Spectrum. American Journal of Surgical Pathology, 2019, 43, 747-754.	2.1	65
42	SMARCA4-deficient Thoracic Sarcomas. American Journal of Surgical Pathology, 2019, 43, 455-465.	2.1	123
43	T₂â€based MRI Deltaâ€radiomics improve response prediction in softâ€tissue sarcomas treated by neoadjuvant chemotherapy.. Journal of Magnetic Resonance Imaging, 2019, 50, 497-510.	1.9	74
44	Pleomorphic Sarcomas. Surgical Pathology Clinics, 2019, 12, 63-105.	0.7	26
45	BAFfling pathologies: Alterations of BAF complexes in cancer. Cancer Letters, 2018, 419, 266-279.	3.2	38
46	Transcriptomic definition of molecular subgroups of small round cell sarcomas. Journal of Pathology, 2018, 245, 29-40.	2.1	235
47	MRI assessment of surrounding tissues in soft-tissue sarcoma during neoadjuvant chemotherapy can help predicting response and prognosis. European Journal of Radiology, 2018, 109, 178-187.	1.2	14
48	Alternative PDGFD rearrangements in dermatofibrosarcomas protuberans without PDGFB fusions. Modern Pathology, 2018, 31, 1683-1693.	2.9	56
49	Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study. BMC Medicine, 2017, 15, 78.	2.3	143
50	<scp>MDM</scp>4 amplification in a case of deâ€differentiated liposarcoma and inâ€silico data supporting an oncogenic event alternative to <scp>MDM</scp>2 amplification in a subset of cases. Histopathology, 2017, 71, 1019-1023.	1.6	13
51	Activity of trabectedin and the PARP inhibitor rucaparib in soft-tissue sarcomas. Journal of Hematology and Oncology, 2017, 10, 84.	6.9	23
52	Update on Families of Round Cell Sarcomas Other than Classical Ewing Sarcomas. Surgical Pathology Clinics, 2017, 10, 587-620.	0.7	43
53	SMARCA4 inactivation defines a group of undifferentiated thoracic malignancies transcriptionally related to BAF-deficient sarcomas. Nature Genetics, 2015, 47, 1200-1205.	9.4	252
54	Consistent SMARCB1 homozygous deletions in epithelioid sarcoma and in a subset of myoepithelial carcinomas can be reliably detected by FISH in archival material. Genes Chromosomes and Cancer, 2014, 53, 475-486.	1.5	120